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Background: The purpose of this prospective cohort study was to compare the costs of 
day hospital (DH) care for hyperglycemic crisis in elderly diabetic patients with those of 
conventional hospitalization (CH). Secondary objectives were to compare these two clinical 
scenarios in terms of glycemic control, number of emergency and outpatient visits,  readmissions, 
hypoglycemic episodes, and nosocomial morbidity.
Methods: The study population comprised diabetic patients aged 74 years consecutively 
admitted to a tertiary teaching hospital in Spain for hyperglycemic crisis (sustained hypergly-
cemia [300 mg/dL] for at least 3 days with or without ketosis). The patients were assigned to 
DH or CH care according to time of admission and were followed for 6 months after discharge. 
Exclusion criteria were ketoacidosis, hyperosmolar crisis, hemodynamic instability, severe 
intercurrent illness, social deprivation, or Katz index D.
Results: Sixty-four diabetic patients on DH care and 36 on CH care were included, with no 
differences in baseline characteristics. The average cost per patient was 1,345.1±793.6 € in the 
DH group and 2,212.4±982.5 € in the CH group (P0.001). There were no differences in number 
of subjects with mild hypoglycemia during follow-up (45.3% DH versus 33.3% CH, P=0.24), 
nor in the percentage of patients achieving a glycated hemoglobin (HbA
1c
) 8% (67.2% DH 
versus 58.3% CH, P=0.375). Readmissions for hyperglycemic crisis and pressure ulcer rates 
were significantly higher in the CH group.
Conclusion: DH care for hyperglycemic crises is more cost-effective than CH care, with a 
net saving of 1,418.4 € per case, lower number of readmissions and pressure ulcer rates, and 
similar short-term glycemic control and hypoglycemia rates.
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Introduction
Diabetes mellitus is a chronic disease with a major socioeconomic impact. In Spain, 
 diabetes-related costs were estimated to be 8,509 million Euros in 2012, 
 representing 8.2% of the national health expenditure.1
The prevalence of diabetes in Spain in 2010 was estimated to be 13.8%, and 
this figure increases progressively with age. In this respect, 20.7% of Spanish men 
over the age of 75 years have a diagnosis of diabetes and 16.7% have undiagnosed 
diabetes.2 In addition, diabetes in the elderly is associated with a higher prevalence 
of other cardiovascular risk factors, coronary heart disease, stroke, premature death, 
 physical disability, and geriatric syndromes.3–9 These data could explain why the popu-
lation aged over 65 years is responsible for 56% of health expenditure on diabetes.10
Hospital admissions have a huge impact on the costs of diabetes to the health 
system,11–13 and in Spain they represent one third of the total cost.1 In this respect, hyper-
glycemic crises are responsible for 7.1% of the hospital costs for diabetes, accounting 
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for 70.7  million Euros in 2012.  Hyperglycemic crises in elderly 
subjects have traditionally required conventional hospitaliza-
tion (CH) for their management. The day hospital (DH) is a con-
solidated form of hospitalization which avoids the drawbacks of 
CH and has social, psychological, medical, and economic 
advantages. DH is beneficial in several disorders where 
patients continue to have good physical activity and where 
medical health education and lifestyle play an important 
role. In this regard, DH has been demonstrated to be 
 effective in the treatment of hyperglycemic crises in younger 
diabetics14,15 and in the management of diseases of the elderly, 
such as Parkinson’s disease, Alzheimer’s disease, and certain 
psychiatric disorders.16–18
The primary aim of this study was to compare the 
 treatment costs of hyperglycemic crises when managed by DH 
and CH in diabetic subjects 74 years of age. The  secondary 
objectives were to compare the effectiveness of these 
two clinical scenarios in terms of glycemic control, emergency 
and outpatient visits, readmissions, rates of  hypoglycemia, 
and in-hospital morbidity.
Materials and methods
A nonrandomized prospective cohort study of patients 74 
years of age admitted for hyperglycemic crises with a 
minimum 6-month follow-up was conducted at the Hospital 
del Mar, Barcelona. The study was approved by the ethics 
 committee of the Hospital del Mar.
Inclusion and exclusion criteria
Patients with sustained hyperglycemia (300 mg/dL) for at 
least 3 days with or without ketosis were included in the study. 
Exclusion criteria were ketoacidosis (venous pH 7.31 and/or 
HCO
3
 22 mEq),  hyperosmolar crisis (glycemia 600 mg/dL 
and effective plasma  osmolarity 320 mOsm/L), unstable 
hemodynamic status or need for ventilatory support, severe 
precipitating factors such as acute myocardial  infarction, 
stroke, sepsis, social deprivation, and dependence for 
four or more activities of daily living (Katz index D).
group assignment
Patients were assigned to the DH group if they were admitted 
to hospital within DH opening hours (week days from 8 am 
to 4 pm); otherwise they were treated in the emergency 
department and subsequently hospitalized. Patients were 
treated following the same protocol for both DH and CH. 
This protocol included initial evaluation with a blood test, 
urinalysis, and a chest radiograph to rule out underlying 
infectious disease, and hourly measurement of glycemia and 
ketonemia. Treatment included hydration with  intravenous 
saline solution as required, an insulin regimen with 
 insulin aspart administered subcutaneously every 2 hours, 
and oral  carbohydrate intake if glucose levels were less 
than 250 mg/dL with persistent ketosis. If an infection 
was diagnosed, appropriate treatment was initiated. Diabetes 
 education was delivered by a specialist diabetes nurse and was 
the same for patients in both groups, with specific attention 
paid to dietary advice, physical activity, and recognition of 
hypoglycemia.
After initial treatment of hyperglycemic crisis (for up 
to 8 hours), DH patients were scheduled for follow-up visits 
at 24, 72 hours, and 7 days to adjust treatment and to complete 
their diabetes education. At discharge, CH patients were 
scheduled for a one-week follow-up visit in the outpatient 
clinic. Measurement of glycated hemoglobin (HbA
1c
) and 
clinical evaluation was scheduled for 3 and 6 months for 
patients in both groups.
At the time of admission for hyperglycemic crisis, data 
on the following baseline characteristics were collected: age, 
sex, weight, height, HbA
1c
, presence of chronic microvascular 
or macrovascular complications, diabetes treatment,  diabetes 
duration, Katz index score, dependence for activities of 
daily living, Charlson comorbidity index score, and degree 
of family support. At the 3-month follow-up, the number 
of mild and severe hypoglycemic episodes, readmissions 
for any diabetes-related or unrelated cause, nosocomial 
complications (hospital-acquired infections and pressure 
ulcers), and number of outpatient and emergency room visits 
were recorded.
Definition of clinical outcomes
“Failure of treatment in DH” was defined as the need for 
CH in the first week after a patient was admitted for treatment 
in DH. This failure could be due to persistent hyperglycemia, 
ketosis or acidosis, severe intercurrent illness, or repeated 
hypoglycemia. Costs of hospital admissions attributed to DH 
failure were included in the cost of DH and not as readmis-
sions. Mild hypoglycemia was defined as capillary glycemia 
60 mg/dL associated with adrenergic symptoms. Following 
the Diabetes Control and Complications Trial criteria, severe 
hypoglycemia was considered to be requirement of assistance 
for recovery or glucagon injection.19
laboratory measurements
Ketone bodies were measured by determination of 
hydroxybutyrate in a capillary blood sample using a ketone 
monitoring system (Precision Xtra®; Abbott Laboratories, 
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North Chicago, IL, USA) and by determination of acetoac-
etate in a urine sample using Ketostix® (Bayer  Corporation, 
Elkhart, UK). HbA
1c
 was measured using a commercial 
chromatographic method (Biosystems,  Barcelona, Spain), 
certified by the National  Glycohemoglobin  Standardization 
Program as having documented traceability to the Diabe-
tes Control and Complication Trial reference method and 
standardized to National Glycohemoglobin Standardization 
Program units.
Costs
Cost calculation included: initial care, pharmacy, complemen-
tary examinations, outpatient care, and readmission. Cost cal-
culations for initial care in CH included emergency room stay 
and subsequent hospitalization. Cost calculations for initial 
care in DH included the DH stay and the costs associated 
with failure of treatment in DH. Outpatient costs included 
outpatient visits and emergency attendances not requiring 
hospital admission.
The methodology of the EuroDRG (Diagnosis-Related 
Groups) project was used for the cost calculations.20 The 
hospital uses a cost accounting system based on full-costing 
allocation that allows for assessing direct costs derived from 
clinical activity. In the present study, cost estimation was 
based on a full-cost accounting system and on the criteria of 
clinical activity-based costing methods to obtain the highest 
sensitivity in the assessment of variability in clinical activity. 
Moreover, this system ensures that the hospital’s total costs 
are distributed among the patients. Allocation was based on 
directly assigning the cost of the following services to the 
patient: laboratory, pharmacy, radiology, nuclear medicine, 
pathology, and prosthetics. The information systems con-
tain exhaustive data on human resources and their activity, 
ie, storage, admissions planning, ambulatory and emergency 
care, operating rooms, diagnostic and complementary tests, 
and interhospital consultations. This information creates and 
automatically updates the cost drivers for overheads.
statistical analysis
Accepting an alpha risk of 0.05 and a beta risk of 0.20 in a 
bilateral contrast, 36 patients would be required in each group 
to detect a difference of 1,000 € or more. The variability 
of cost, according to our institution’s economic research 
department, was 1,423 €. A loss to follow-up of 10% was 
assumed.
Data were expressed as the mean ± standard deviation 
for continuous variables and as percentages and frequencies 
for categorical variables. The Student’s t-test was performed 
to assess differences between two means. The chi-squared 
or Fisher’s exact tests were used to evaluate the degree of 
association of categorical variables. A P-value 0.05 was 
 considered to be statistically significant. The statistical  analysis 
was done with Statistical Package for the Social  Sciences 
version 12 software (SPSS Inc., Chicago, IL, USA).
Results
During the study period, a total of 100 diabetic patients 
aged 74 years and older were included, ie, 36 in the CH 
group and 64 in the DH group. The mean age was 80.4±4.8 
(75–95) years and 63% of the patients were female. 
Ninety-eight patients had type 2 diabetes and two had 
corticosteroid-induced diabetes. With regard to type of 
hyperglycemic crisis, 64% had acute hyperglycemia without 
ketosis (300 mg/dL) and 36% presented with ketosis. The 
groups were comparable in terms of age, sex, body mass 
index, Katz index, and socioeconomic and diabetes charac-
teristics. Biochemical parameters at the time of admission 
were also comparable (Table 1). Precipitating factors for 
hyperglycemic crisis were infection (40%), nonadherence 
to treatment (14%), corticosteroid therapy (12%), new-onset 
diabetes (11%), and other causes in the remaining 23%. 
At discharge, 73.5% of patients were on neutral protamine 
Hagedorn or premixed insulin twice daily, 4.1% were on 
insulin glargine once daily, and 6.2% were on oral medi-
cations (metformin or sulfonylureas), with no differences 
between groups (P=0.109).
Clinical results
A progressive reduction in HbA
1c 
levels was observed 
at 3-month and 6-month-follow-up, with no differences 
between groups (Figure 1). Most of the patients had 
reached an HbA
1c
 8% at the end of follow-up (Figure 2). 
Only one patient in each group had severe hypoglycemia 
that occurred during the first 15 days. Twelve subjects 
in the CH group and 29 in DH group suffered at least 
one mild  hypoglycemic episode during follow-up (33.3% 
 versus 45.3%, P=0.24).
Average stay was 9.0±3.2 days in the CH group and a 
maximum of 8 hours in the DH group (P0.001). The num-
ber of outpatient visits was greater in the DH group given the 
protocol for this particular group. However, no difference was 
observed in the number of emergency department  admissions. 
The number of readmissions for any cause at 3 months was 
higher in the CH group, but was not statistically  significant. 
 However, readmission rates for diabetes at 3 months were 
 significantly higher in the CH group (Table 2). There were 





Table 1 Baseline characteristics





Age (years) 80.3±4.8 80.6±4.6 0.786
Female sex (%) 67.2% 55.6% 0.173
BMI (kg/m2) 26.1±4.9 25.5±5.1 0.665
Katz A or B index (%) 72.2 72.2 0.529
Charlson comorbidity index 3.2±2.0 3.3±1.7 0.936
Family support (%) 88.1 97.1 0.136
Diabetes duration (years) 14.4±8.0 17.4±11.2 0.220
Microvascular complications (%) 38.8 38.2 0.699
Macrovascular complications (%) 33.1 37.1 0.633
Insulin therapy (%) 30.4 22.9 0.298
hbA1c (%) 10.9±1.9 10.7±2.1 0.667
hbA1c (mmol/mol) 96.1±21.0 94.1±23.5 0.667
Venous glucose (mg/dl) 420.0±74.8 451.0±98.6 0.108
Venous ph 7.39±0.06 7.40±0.05 0.404
Weight loss within previous 3 months (kg) 2.97±3.66 1.4±2.8 0.058

















Day hospital Conventional hospitalization
Figure 1 glycated hemoglobin (hbA1c) levels during follow-up.




















Figure 2 Percentage of patients achieving glycated hemoglobin (hbA1c) 8%.
three cases (4.6%) of DH treatment failure, two cases 
due to persistent hyperglycemia, and one case in the context 
of nonadherence to treatment. With regard to nosocomial 
complications, five patients (13.8%) in the CH group and 
none in the DH group developed superficial noninfected 
pressure ulcers (P=0.002), and one was diagnosed with a 
nosocomial urinary tract infection.
Financial cost results
Although DH care generated more outpatient costs, the 
overall cost of CH was clearly higher (Table 3).
Discussion
DH care for diabetic patients with hyperglycemic crisis 
was an efficient practice, saving 1,418.4 € per patient. 
 Moreover, there were no differences in glycemic control or 
in the number of hypoglycemic events in the medium term, 
and DH patients did not suffer pressure ulcers and required 
less frequent diabetes-related readmission. This finding is 
important when considering the economic impact of  diabetes 
on health systems. The annual health care expenditure asso-
ciated with diabetes in the USA in 2007 was 174  billion 
 dollars, of which 116 were associated with medical expenses 
and 58 with loss of labor hours. Further, the estimated 
annual cost associated with a case of diabetes in Spain 
is 1,770 €.10 The economic benefit of DH care found in the 
present study is even more relevant if we take into consid-
eration that elderly patients account for much of the health 
spending on diabetes.10
In the present study, DH care for elderly patients with 
hyperglycemic crisis avoided the costs associated with 
 hospitalization, which accounted for approximately 85% of 
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Table 2 study endpoints
Day hospital Conventional  
hospitalization
P-value
Outpatient visits (n) 5.0±2.2 2.5±2.0 0.012
emergency room admissions 0.2±0.6 0.2±0.4 0.590
readmission for any cause (%) 4 (6.3) 7 (19.4) 0.085
Diabetes-related readmissions (%) 1 (1.6) 5 (13.9) 0.040
the total cost in the CH group. It should be stressed that the 
cost of diabetes in the last year of life is mainly associated with 
a higher rate of hospitalization; moreover, the length of stay 
is 70% longer than in nondiabetic patients and it is associated 
with a greater number of complications, such as nosocomial 
infections, pressure ulcers, and adverse drug reactions.21
Despite a higher cost for outpatient visits (DH care 
includes three follow-up visits in the first week) and 
three hospital admissions due to failure of DH care, DH is 
clearly beneficial when we compare the total costs of CH.
In addition to the economic benefits, DH had further 
advantages over CH. First, we observed a reduction in read-
missions for diabetes. This may reflect the fact that patients 
treated by CH are living outside their usual environment and 
must adapt to a different routine, food intake, and physi-
cal activity. Thus, when patients are discharged, return to 
everyday habits may destabilize glycemic control and lead 
to readmission. Second, DH care prevented nosocomial 
complications, mainly the pressure ulcers that were present in 
approximately one in seven patients in the CH group. Third, 
other potential benefits not evaluated in the present study, 
but which may hypothetically favor DH care, are related to 
functional improvement, less emotional impact on the lives 
of the elderly, and a minor impact on the family.
Since the UK Prospective Diabetes Study showed an 
improvement in the risk of microvascular  complications 
with intensive glycemic control, scientific societies have 
established the goal of HbA
1c
 7% for all subjects with 
type 2 diabetes mellitus.22 The ACCORD (Action to 
Control Cardiovascular Risk in Diabetes),23 ADVANCE 
(Action in Diabetes and Vascular Disease: Preterax® 
[Servier  International, Neuilly sur Seine, France] and 
 Diamicron MR Controlled Evaluation),24 and VADT25  studies, 
 published in 2009, designed for the diabetic population with 
an average age around 65 years and longstanding diabetes, 
showed that strict glycemic control had no effect on the risk 
of cardiovascular events, and was associated with increased 
mortality from all causes in the ACCORD study.23 This 
has led to a recommendation for less  stringent control (HbA
1c
 
8%) for patients with longstanding  diabetes, fragility, and/
or cardiovascular disease, which represents the majority of 
elderly diabetic patients.26,27 In the present study, over 85% 
of patients in both groups achieved an average HbA
1c
 8% 
at 6 months, and therefore adjusted to current goals.
Since the metabolic goal in this study was nonaggressive, 
ie, HbA
1c
 8%, there were few episodes of hypoglycemia 
in both groups. Nevertheless, it is important to emphasize 
that we found no difference in the number of hypoglycemic 
events between the groups. Hypoglycemia in the elderly 
can be associated with potentially serious consequences,28 
so treatment of diabetes in this age group should aim to 
minimize this risk.29,30
Evidence-based guidelines for many health conditions 
that affect the elderly are deficient owing to the lack of 
studies in this age group; thus, the tendency is to extrapo-
late evidence from younger age groups. Several authors 
propose a change in patient care in the last years of life, 
advocating overall management rather than focusing on 
the different comorbidities.31,32 We consider DH care for 
hyperglycemic crisis to be in line with this new concept 
in the care of the elderly and their use could be extended 
to other chronic illnesses.
Table 3 Costs of treatment
Day hospital Conventional hospitalization P-value
Initial care (€) 580.2±489.1 2,013.6±790.4 0.001
Complementary examinations (€) 123.7±276.3 281.3±188.1 0.007
Pharmacy (€) 12.8±95.6 20.3±24.8 0.676
Outpatient visits (€) 116.7±75.3 56.9±105.7 0.003
readmissions (€) 340.8±1190 288.3±916.8 0.835
Total (€) 1,345.1±793.6 2,212.4±982.5 0.001





The limitations of the present study are mainly related to 
the study design, given that patients were not randomly allo-
cated to treatment groups. The method of assigning patients 
according to time of arrival at the emergency room could be a 
weakness: however, the bulk of hospital care is known to be 
concentrated during the day and less at night,33 and it is note-
worthy that both groups had similar baseline characteristics. 
Moreover, severe hyperglycemic crisis was not included in 
the present study, so its results cannot be generalized to the 
treatment of these severe cases. We only estimated costs 
at the hospital level and other costs, such as use of social 
resources, and those arising from off-work relatives were 
not taken into account.
Conclusion
When compared with CH, DH care for elderly diabetic 
patients with hyperglycemic crisis is an efficient practice in 
terms of expenditure, safety, and metabolic control.
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